Earnings Releases·Nov 12, 2026, 8:34 AM ET

Corteva — Third Quarter 2026 Earnings Summary

Q3 2026 Net Sales fell 9% year-over-year to $1.59 billion, driven by a 7% price decline and 2% volume drop, while Adjusted Pro Forma Operating EBITDA decreased 17% to $222 million; full-year Net Sales are down 1% to $5.36 billion.
Full-year 2026 Adjusted Pro Forma Operating EBITDA guidance was lowered to $1.1–$1.125 billion and EPS guidance to $0.76–$0.80, reflecting significantly weaker market conditions in Brazil compared to prior expectations.
Regional performance diverged sharply, with Latin America suffering a 31% Organic Sales decline due to farmer liquidity constraints and inventory issues, while North America, EMEA, and Asia Pacific posted growth of 7%, 14%, and 5% respectively.
The company expects to incur $130–$140 million in net pre-tax restructuring charges in 2026 for Crop Protection network optimization, with activities projected to conclude in 2028.
The Board authorized the first common dividend post-spin, and management reaffirmed its strategy focusing on new product innovation and disciplined execution despite concentrated pricing pressure in mature molecules.